This hypoglycemic method does not depend on insulin secretion or sensitivity; therefore, it is also effective in diabetic patients with insulin resistance.[38,39] Currently, various SGLT-2 inhibitors have been launched globally, such as dapagliflozin, empagliflozin, and canagliflozin. This evidence concerns the gene SLC5A2 and Insulin resistance.